Yttrium-90 and Rhenium-188 Radiopharmaceuticals for Radionuclide Therapy

More documents

Recommendations

Info

[13.18] ALBERTO, R., et al., A novel organometallic aqua complex of technetium for the labeling of biomolecules: Synthesis of [ 99m Tc(OH 2 ) 3 (CO) 3 ] + from [ 99m TcO 4 ] – in aqueous solution and its reaction with a bifunctional ligand, J. Am. Chem. Soc. 120 (1998) 7987. [13.19] SCHIBLI, R., et al., Influence of the denticity of ligand systems on the in vitro and in vivo behavior of Tc-99m(I)-tricarbonyl complexes: A hint for the future functionalization of biomolecules, Bioconjug. Chem. 11 (2000) 345. [13.20] BANERJEE, S.R., et al., Bifunctional single amino acid chelates for labeling of biomolecules with the {Tc(CO) 3 } + and {Re(CO) 3 } + cores. Crystal and molecular structures of [ReBr(CO) 3 (H 2 NCH 2 C 5 H 4 N)], [Re(CO) 3 {(C 5 H 4 NCH 2 ) 2 NH}]Br,[Re (CO) 3 {(C 5 H 4 NCH 2 ) 2 NCH 2 CO 2 H}]Br, [Re(CO) 3 {X(Y)NCH 2 CO 2 CH 2 CH 3 }]Br (X=Y=2-pyridylmethyl; X=2-pyridyimethyl, Y = 2-(1-methylimidazolyl)methyl; X=Y=2-(1-methylimidazolyl)methyl), [ReBr(CO) 3 {(C 5 H 4 NCH 2 )NH(CH 2 C 4 H 3 S)}], and [Re(CO) 3 {(C 5 H 4 NCH 2 )N(CH 2 C 4 H 3 S)(CH 2 CO 2 )}], Inorg. Chem. 41 (2002) 6417. [13.21] NANCOLLAS, G.H., et al., Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite, Bone 38 (2006) 617. [13.22] KUBÍČEK, V., KOTEK, J., HERMANN, P., LUKEŠ, I., Aminoalkyl bis (phosphonates): Their complexation properties in solution and in the solid state, Eur. J. Inorg. Chem. 2007 (2007) 333. [13.23] LECOUVEY, M., LEROUX, Y., Synthesis of 1-hydroxy-1,1-bisphosphonates, Heteroat. Chem. 11 (2000) 556. [13.24] SCHIBLI, R., et al., Steps toward high specific activity labeling of biomolecules for therapeutic application: Preparation of precursor [ 188 Re(H 2 O) 3 (CO) 3 ] + and synthesis of tailor-made bifunctional ligand systems, Bioconjug. Chem. 13 (2002) 750. [13.25] PARK, S.H., SEIFERT, S., PIETZSCH, H.J., Novel and efficient preparation of precursor [ 188 Re(OH 2 ) 3 (CO) 3 ] + for the labeling of biomolecules, Bioconjug. Chem. 17 (2006) 223. [13.26] DE ROSALES, R.T.M., et al., 188 Re(CO) 3 -dipicolylamine-alendronate: A new bisphosphonate conjugate for the radiotherapy of bone metastases, Bioconjug. Chem. 21 (2010) 811. [13.27] DE ROSALES, R.T.M., FINUCANE, C., MATHER, S.J., BLOWER, P.J., Bifunctional bisphosphonate complexes for the diagnosis and therapy of bone metastases, Chem. Commun. (2009) 4847. [13.28] RIESE, C.G.U., SEITZ, S., SCHIPPER, M., BEHR, T., Effective treatment of pancreatic neuroendocrine tumours transfected with the sodium iodide symporter gene by 186 Re-perrhenate in mice, Eur. J. Nucl. Med. Mol. Imaging 36 (2009) 1767. [13.29] WAIBEL, R., et al., Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex, Nat. Biotechnol. 17 (1999) 897. [13.30] DEMAIMAY, F., et al., Rhenium-188 and technetium-99m nitridobis (N-ethoxy-Nethyldithiocarbamate) leucocyte labelling radiopharmaceuticals: [Re-188-N(NOET) 2 ] and [Tc-99m-N(NOET) 2 ], NOET = Et(EtO)NCS 2 : Their in vitro localization and chemical behavior, Nucl. Med. Biol. 24 (1997) 701. 260
[13.31] DE ROSALES, R.T.M., et al., Synthesis of 64 Cu(II)-bis(dithiocarbamatebisphosphonate) and conjugation with superparamagnetic iron oxide nanoparticles: In vivo evaluation as dual-modality PET-MRI agent, Angew. Chem. Int. Ed. 123 (2011) 5623. [13.32] STALTERI, M.A., et al., Uptake of Tc-99m-nitrido dithiocarbamate complexes by tumour cells, Nucl. Med. Commun. 18 (1997) 870. 261
Page 1 and 2:
IAEA RADIOISOTOPES AND RADIOPHARMAC
Page 3 and 4:
YTTRIUM-90 AND RHENIUM-188 RADIOPHA
Page 5 and 6:
IAEA RADIOISOTOPES AND RADIOPHARMAC
Page 7 and 8:
FOREWORD The IAEA helps to promote
Page 9 and 10:
CONTENTS CHAPTER 1. INTRODUCTION ..
Page 11 and 12:
7.4. Discussion ...................
Page 13 and 14:
CHAPTER 12. DEVELOPMENT OF 90 Sr/ 9
Page 15 and 16:
Chapter 1 INTRODUCTION 1.1. BACKGRO
Page 17 and 18:
devices were designed to improve th
Page 19 and 20:
etention of the antibody’s target
Page 21 and 22:
Binding affinity of these derivativ
Page 23 and 24:
Chapter 2 FUNDAMENTAL CONCEPTS IN R
Page 25 and 26:
A special characteristic of radioph
Page 27 and 28:
β particles emitted by 90 Y. Numer
Page 29 and 30:
2.3.1. Exploitation of certain meta
Page 31 and 32:
2.3.3. Antibodies The high specific
Page 33 and 34:
cell cultures, presents one example
Page 35 and 36:
Another very promising form of radi
Page 37 and 38:
destructive processes within the jo
Page 39 and 40:
esearch efforts, since then. Howeve
Page 41 and 42:
[2.18] HAMILTON, J.G., The metaboli
Page 43 and 44:
[2.52] GOLDENBERG, D.M., et al., Mu
Page 45 and 46:
Chapter 3 DEVELOPMENT OF RADIOPHARM
Page 47 and 48:
FIG. 3.3. Elution efficiencies for
Page 49 and 50:
FIG. 3.5. Electrodeposition of yttr
Page 51 and 52:
The results of the experiments of r
Page 53 and 54:
TABLE 3.3. RESULTS FOR 90 Sr/ 90 Y
Page 55 and 56:
FIG. 3.11. Elution yield of a 90 Sr
Page 57 and 58:
According to Fig. 3.12, there is a
Page 59 and 60:
eagent (Sigma). The mean recovery o
Page 61 and 62:
FIG. 3.18. Variation of RCP (%) of
Page 63 and 64:
(20 and 30 min) and volume of 188 R
Page 65 and 66:
FIG. 3.24. Variation of labelling y
Page 67 and 68:
(c) Clodronate: 20 mg of clodronate
Page 69 and 70:
Chapter 4 EVALUATION OF THE 90 Sr/
Page 71 and 72:
Kamadhenu consists of five main com
Page 73 and 74:
Quality control of radiolabelling w
Page 75 and 76:
The electrochemical deposition of 9
Page 77 and 78:
FIG. 4.5. Typical pattern of the wh
Page 79 and 80:
FIG. 4.6. Elution profile from the
Page 81 and 82:
FIG. 4.8. CD20 recognition in Ramos
Page 83 and 84:
4.5. RECOMMENDATIONS AND FUTURE WOR
Page 85 and 86:
adioiodine labelled anti-NCAM antib
Page 87 and 88:
FIG. 5.1. Comparison of biodistribu
Page 89 and 90:
FIG. 5.3. Three step strategy. Biot
Page 91 and 92:
TABLE 5.1. THREE STEP PRETARGETING:
Page 93 and 94:
5.1.4. Therapeutic experiments with
Page 95 and 96:
5.1.4.4. Conclusion The radioiodine
Page 97 and 98:
control procedure for detection of
Page 99 and 100:
6.1.3. Recovery of doped 85/89 Sr 2
Page 101 and 102:
6.2. PREPARATION AND BIOEVALUATION
Page 103 and 104:
(a) (b) (c) FIG. 6.5. PD-10 column
Page 105 and 106:
FIG. 6.7. SDS PAGE pattern of ritux
Page 107 and 108:
FIG. 6.10. HPLC pattern of pure 90
Page 109 and 110:
FIG. 6.13. Cell binding studies wit
Page 111 and 112:
6.2.1.6. Conclusion The procedure f
Page 113 and 114:
FIG. 6.17. Elution profile of 90 Y
Page 115 and 116:
form NADH, which, in turn, causes t
Page 117 and 118:
FIG. 6.19. In vivo distribution pat
Page 119 and 120:
ACKNOWLEDGEMENTS The authors of thi
Page 121 and 122:
Chapter 7 DEVELOPMENT OF THERAPEUTI
Page 123 and 124:
the residual breast tissue becoming
Page 125 and 126:
7.2.5.2. Automatic procedure The la
Page 127 and 128:
FIG. 7.2. RCP values of 90 Y r-BHD
Page 129 and 130:
FIG. 7.3. Pyrogen test shows result
Page 131 and 132:
to avidin at the 1:4 avidin:r-BHD m
Page 133 and 134:
[7.9] SU, F.M., GUSTAVSON, L.M., AX
Page 135 and 136:
8.1. INTRODUCTION In past years, th
Page 137 and 138:
(a) FIG. 8.1. (a) Schematic illustr
Page 139 and 140:
Preliminary synthesis of the biotin
Page 141 and 142:
(a) (b) FIG. 8.4. (a) PEGylated and
Page 143 and 144:
TABLE 8.2. BIODISTRIBUTION IN RATS
Page 145 and 146:
A specific binding to avidin was ev
Page 147 and 148:
[8.13] BOSCHI, A., DUATTI, A., UCCE
Page 149 and 150:
90 Y solution obtained from a 90 Sr
Page 151 and 152:
From each fraction, a ~1 g aliquot
Page 153 and 154:
FIG. 9.2. Relationship between 90 S
Page 155 and 156:
with 188 Re obtained from the 188 W
Page 157 and 158:
9.3.2. Labelling of DPA ale DPA ale
Page 159 and 160:
FIG. 9.8. TLC radiochromatogram of
Page 161 and 162:
(-) 188 Re(CO) 3 (+) (-) 99m Tc(CO)
Page 163 and 164:
the HSA solution containing sodium
Page 165 and 166:
TABLE 9.3. RESULTS OF 99m Tc LABELL
Page 167 and 168:
9.4.4. Yttrium-90 and 177 Lu labell
Page 169 and 170:
FIG. 9.14. In vitro stability of 90
Page 171 and 172:
(a) (b) (c) (d) (e) (f) (g) (h) (i)
Page 173 and 174:
TABLE 9.8. YTTRIUM-90 CITRATE COLLO
Page 175 and 176:
(a) (b) FIG. 9.17. Grain size distr
Page 177 and 178:
TABLE 9.10. BIODISTRIBUTION AFTER A
Page 179 and 180:
FIG. 9.19. Structure of DOTA biotin
Page 181 and 182:
[9.8] WESTERA, G., GADZE, A., HORST
Page 183 and 184:
Chapter 10 DEVELOPMENT, PREPARATION
Page 185 and 186:
acidic pH) and the vial heated for
Page 187 and 188:
10.2.2.1. Materials and methods (a)
Page 189 and 190:
Using a semiquantitative method, th
Page 191 and 192:
FIG. 10.3. Whole body, SPECT and ta
Page 193 and 194:
TABLE 10.4. ORGAN DISTRIBUTION STUD
Page 195 and 196:
was assessed by measuring the relea
Page 197 and 198:
—— Biological studies: The whol
Page 199 and 200:
or liver) (see Fig. 10.7). The resu
Page 201 and 202:
(b) Results and discussion Healthy
Page 203 and 204:
and the pellet (particles of HA lab
Page 205 and 206:
FIG. 10.11. Organ distribution stud
Page 207 and 208:
The procedure was as follows: —
Page 209 and 210:
TABLE 10.5. INFLUENCE OF CHEMICAL I
Page 211 and 212:
analysed using ICP OES was within t
Page 213 and 214:
suggested for separation of pure 86
Page 215 and 216:
adionuclidic purity of the 90 Y sol
Page 217 and 218:
FIG. 10.16. (a) Strontium-90/yttriu
Page 219 and 220:
[10.5] DJOKIĆ, D.J., JANKOVIĆ, D.
Page 221 and 222:
Yttrium-90 is one of the radionucli
Page 223 and 224: (a) (b) (c) The generator was prepa
Page 225 and 226: —— Development of EPC: The EPC
Page 227 and 228: FIG. 11.4. Elution curve of 90 Sr e
Page 229 and 230: 11.4. YTTRIUM-90 MAbs The use of th
Page 231 and 232: FIG. 11.6. RCP measured using ITLC
Page 233 and 234: FIG. 11.9. Biodistribution of 90 Y
Page 235 and 236: 11.5. YTTRIUM-90 EDTMP Bone metasta
Page 237 and 238: FIG. 11.14. Electrophoresis of 90 Y
Page 239 and 240: FIG. 11.15. Particle size distribut
Page 241 and 242: 11.7. CONCLUSION During this CRP, a
Page 243 and 244: Chapter 12 DEVELOPMENT OF 90 Sr/ 90
Page 245 and 246: 12.1.1.4. Acid vapour trap and radi
Page 247 and 248: 12.1.8. Yttrium-90 peptide labellin
Page 249 and 250: (a) FIG. 12.3. Yttrium-90 elution p
Page 251 and 252: FIG. 12.6. HPLC of 90 Y DOTATATE. 1
Page 253 and 254: Chapter 13 BIFUNCTIONAL BISPHOSPHON
Page 255 and 256: latter requirement [13.10]. When th
Page 257 and 258: whether the organometallic core sel
Page 259 and 260: The fate of a targeted imaging prob
Page 261 and 262: FIG. 13.7. SPECT/CT images showing
Page 263 and 264: FIG. 13.9. TLC SG analyses of [ 188
Page 265 and 266: FIG. 13.11. Stability study (toward
Page 267 and 268: Ex vivo biodistribution studies at
Page 269 and 270: was in the form of either pertechne
Page 271 and 272: FIG. 13.19. Absolute uptake of 99m
Page 273: [13.2] ZHANG, S., GANGAL, G., ULUDA
Page 277 and 278: The activity due to 90 Sr should be
Page 279 and 280: 14.3.1.2. Operation of the 90 Sr/ 9
Page 281 and 282: antibody were taken, to which 90 Y
Page 283 and 284: operation, radiopharmaceutical grad
Page 285 and 286: 14.4.1.3. Operation of the stage II
Page 287 and 288: A typical EPC pattern for a 90 Y pr
Page 289 and 290: FIG. 14.10. Decay curve of carrier
Page 291 and 292: FIG. 14.12. ITLC of 90 Y rituximab.
Page 293 and 294: FIG. 14.13. Reaction scheme for lab
Page 295 and 296: TABLE 14.6. STABILITY (%) OF 90 Y D
Page 297 and 298: FIG. 14.18. Microsphere albumin siz
Page 299: [14.3] PANDEY, U., DHAMI, P.S., JAG
Page 302 and 303: naphthalene and 1.2 g of 2,5-diphen
Page 304 and 305: A-2.2. Materials The method for sep
Page 306 and 307: out using a Wallac 1411 spectromete
Page 308 and 309: A-5.3. Procedure The technique was
Page 310 and 311: Although acyclic chelators offer ma
Page 312 and 313: (b) (c) and 90 Y colloids, both ser
Page 315: CONTRIBUTORS TO DRAFTING AND REVIEW
Page 318 and 319: INDIA Allied Publishers 1 st Floor,
Page 320: A key requirement for the effective
show all

Yttrium-90 and Rhenium-188 Radiopharmaceuticals for Radionuclide Therapy

Create successful ePaper yourself

Delete template?

Save as template?